Quantiferon‐Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV ‐specific CD 8+ T‐cell reconstitution in pediatric hematopoietic stem cell transplant patients

• Published in: Pediatric transplantation 2018-08, Vol.22 (5)
• Main Authors: Paouri, Bilio, Soldatou, Alexandra, Petrakou, Eftihia, Theodosaki, Maria, Tsentidis, Charalampos, Kaisari, Katerina, Oikonomopoulou, Christina, Matsas, Minos, Goussetis, Eugenios
• Format: Article
• Language: English
• ISSN: 1397-3142; 1399-3046
• DOI: 10.1111/petr.13220

Pediatric HSCT recipients are at high risk for CMV reactivation due to their immature immune system and therapy following transplantation. Reconstitution of CMV ‐specific T‐cell immunity is associated with control and protection against CMV . The clinical utility of monitoring CMV ‐specific CMI to predict CMV viremia in pediatric HSCT patients using the Quantiferon‐ CMV ( QIAGEN ® ) test was investigated prospectively. Thirty‐seven pediatric allogeneic HSCT recipients were enrolled from 3/2010‐6/2012. CMV viremia was detected via weekly real‐time PCR . The Quantiferon‐ CMV test was conducted pretransplant, early after transplantation, 30, 90 , 180 , 270, and 360 days post‐transplantation. The incidence of CMV viremia was 51% (19/37) with half of the episodes within ≤30 days post‐transplant. Fifteen patients showed CMV ‐specific immunity (average of 82 days). The cumulative incidence of CMV reactivation in patients who developed CMV ‐specific immunity was lower than those who did not (15% vs 53%; P  = .023). The ROC statistical analysis showed that the AUC was 0.725 in predicting viremia, for Quantiferon‐ CMV test. In this cohort, the Quantiferon‐ CMV assay was a valuable method for identifying pediatric HSCT patients at high risk for CMV viremia, suggesting potential clinical utility to individualize patient's management post‐transplant.